John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics, and Genetics Institute. He built a hematology therapeutic business that reached over $1 billion in annual revenue for Wyeth/Genetics Institute and was responsible for leading the development of the fastest biologic to progress from phase I to FDA approval. John started his career in research and development as one of the first employees at Genzyme. He received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.
Edwards, John
John Edwards
Executive Chair
x
John Edwards
Executive Chair
John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics, and Genetics Institute. He built a hematology therapeutic business that reached over $1 billion in annual revenue for Wyeth/Genetics Institute and was responsible for leading the development of the fastest biologic to progress from phase I to FDA approval. John started his career in research and development as one of the first employees at Genzyme. He received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.
